Olema Pharmaceuticals, Inc. Operating Income (Loss) in USD from 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Olema Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to Q3 2025.
  • Olema Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$45.9M, a 21.9% decline year-over-year.
  • Olema Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$165M, a 21.7% decline year-over-year.
  • Olema Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$142M, a 35.5% decline from 2023.
  • Olema Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$105M, a 1.9% increase from 2022.
  • Olema Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$107M, a 49.7% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

Olema Pharmaceuticals, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$165M -$45.9M -$8.26M -21.9% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 -$157M -$47.9M -$14.3M -42.8% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 -$143M -$34.9M -$534K -1.56% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 -$142M -$36.8M -$6.35M -20.9% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-18
Q3 2024 -$136M -$37.6M -$14.3M -61.2% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 -$122M -$33.5M -$11.9M -55.2% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 -$110M -$34.3M -$4.74M -16% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 -$105M -$30.4M -$3.2M -11.7% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-18
Q3 2023 -$102M -$23.3M -$120K -0.52% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$102M -$21.6M +$11.7M +35.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$113M -$29.6M -$6.35M -27.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$107M -$27.2M -$5.46M -25.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 -$102M -$23.2M -$5.46M -30.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$96.1M -$33.3M -$16.8M -102% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$79.3M -$23.3M -$7.8M -50.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$71.5M -$21.8M -$11.6M -115% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$59.9M -$17.8M -$9.89M -126% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$50M -$16.5M -$14M -565% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$35.9M -$15.5M -$14.4M -1381% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$21.5M -$10.1M Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$7.87M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$2.49M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$1.04M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11

Olema Pharmaceuticals, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$142M -$37.3M -35.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-18
2023 -$105M +$2.03M +1.9% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-18
2022 -$107M -$35.5M -49.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-11
2021 -$71.5M -$50M -232% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 -$21.5M -$17.2M -398% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-28
2019 -$4.32M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.